A Missouri court has approved a $7.25 billion settlement by German pharmaceutical and chemical company Bayer to resolve thousands of claims alleging that its Roundup weedkiller causes cancer.
Judge Timothy Boyer granted final approval on Friday to an agreement covering people diagnosed with non-Hodgkin lymphoma following alleged exposure to the herbicide, including those who may develop the disease in the future after exposure before February 17, 2026. Bayer will distribute compensation over 21 years, with individual payments expected to range from approximately $10,000 to $165,000, depending on factors including age, illness severity and exposure history.
The company inherited the litigation through its $63 billion acquisition of Monsanto in 2018 and has since spent at least $14 billion defending and settling Roundup-related claims. Bayer chief executive Bill Anderson welcomed the decision as a major step towards resolving the legal dispute, although approximately 200 federal cases remain outside the agreement and appeals could delay compensation.
The ruling follows years of controversy surrounding glyphosate, Roundup’s principal ingredient, which the World Health Organization’s cancer research agency classified as probably carcinogenic in 2015. The Environmental Protection Agency maintains that glyphosate is unlikely to cause cancer when used according to instructions, although its latest safety review remains ongoing.
Bayer continues to defend the product’s safety and has removed glyphosate from newer residential formulations while retaining it in agricultural products.